1050 related articles for article (PubMed ID: 15617852)
41. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Kurtz TW; Pravenec M
J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
[TBL] [Abstract][Full Text] [Related]
42. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
43. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
44. An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice.
Takasu T; Kakuta H; Sasamata M; Yamagishi S
Int J Biomed Sci; 2006 Dec; 2(4):333-6. PubMed ID: 23675001
[TBL] [Abstract][Full Text] [Related]
45. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
46. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
Fujimura A; Ushijima K; Ando H
Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691
[No Abstract] [Full Text] [Related]
47. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
[TBL] [Abstract][Full Text] [Related]
48. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
[TBL] [Abstract][Full Text] [Related]
49. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
[TBL] [Abstract][Full Text] [Related]
50. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
51. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
52. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
54. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Francischetti EA; Celoria BM; Francischetti A; Genelhu VA
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):289-303. PubMed ID: 18327991
[TBL] [Abstract][Full Text] [Related]
55. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
56. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
57. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
58. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
59. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
[TBL] [Abstract][Full Text] [Related]
60. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
